Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant study

This study is for older patients (60 years and above) with a type of lymphoma (blood cancer) called diffuse large B-cell lymphoma that has come back or stopped responding to treatment, and who are not well enough for an intensive stem cell transplant. The study is testing a chemotherapy combination called R-IE (Rituximab, Ifosfamide, and Etoposide) given every three weeks for six cycles, followed by two additional doses of Rituximab. A single injection of pegfilgrastim is given after each cycle to protect the immune system. The goal is to see if this outpatient treatment can control the lymphoma and improve quality of life. You may be eligible if: - You are 60 years of age or older - You have CD20-positive diffuse large B-cell lymphoma that has relapsed or is not responding to first-line treatment, and you are not suitable for high-dose chemotherapy/stem cell transplant - Your general health is good enough (ECOG performance status 0 to 2) - Your expected survival is at least 3 months - You are able to give written consent You may NOT be eligible if: - You have severe heart, liver, breathing, or kidney problems - You are pregnant or breastfeeding - You have a known allergy to E. coli proteins, or severe allergy to mouse-derived proteins - You are unable to give written consent Talk to your doctor about whether this trial might be right for you.